Rajashekar Palleti 1, Pawan Kumar2, Pradeep Kumar2, Sandeep Chakraborty1, Sujeet Kumar Mewar2, Sudheer Kumar Arva3, Rama Jayasundar2, and Rajeev Narang4
1CTVS, AIIMS, NEW DELHI, DELHI, India, 2NMR, AIIMS, NEW DELHI, DELHI, India, 3Pathology, AIIMS, NEW DELHI, DELHI, India, 4Cardiology, AIIMS, NEW DELHI, DELHI, India
Synopsis
Keywords: Vessels, Heart, NMR spectroscopy
Motivation: Heart valve disease (HVD) is a multifactorial process and its pathophysiology has not been fully understood.
Goal(s): To investigate and determine the metabolite tissue using the 1H-NMR based metabolomics study to discriminate the aortic valve and mitral valve.
Approach: proton NMR spectroscopy
Results: The results obtained from PLS-DA and VIP score plots of metabolites in tissue showed a separation between patients with aortic valves and mitral valves.
Impact: The present study revealed discrimination of metabolic profiling of tissue
of aortic valve patients from mitral valve replacement implying that 1H-NMR-based
metabolomics may provide an insight into understanding the potential metabolic
alteration.
Introduction
Heart valve disease (HVD) is a common term that
includes several etiologic entities with different pathophysiologic mechanisms
that lead to anatomic disruption of the valve apparatus. Functional abnormalities
due to alterations in matrix architecture and cellular components impair the
function of heart valves resulting in abnormal blood flow patterns through the
chambers of the heart. Degenerative and
rheumatic HVD is caused by the interaction of several risk factors such as
infections, age-related changes, ischemic heart disease, congenital, heart
failure, stroke, genetic, inflammatory, autoimmune, and oxidative stress. Thus, to investigate the metabolic
profiling of aortic, mitral, and double valve repair and replacement (aortic
and mitral valve) tissue samples of patients using proton (1H) NMR spectroscopy.
Methods
Tissue samples were collected from HVD patients with aortic valves (n =9) and mitral
valve (n=11) after valve repair and replacement and stored at -80°C until NMR
experiments were performed. Water-soluble metabolites were extracted from heart
valve tissue using perchloric acid extraction (PCA). The frozen tissue was
weighted, crushed, sonication then thoroughly homogenized in 6% PCA. The
homogenate tissue was centrifuged at 10,000 rpm at 4 o C for 10 minutes. After
centrifuging supernatant will be collected and then neutralized using 3M KOH to
pH 7.4 and the precipitate was removed by centrifugation. The supernatant
obtained will be lyophilized for 8 to 10 hours at -80oC. The resulting sample
will be dissolved in 0.6mL of Deuterium oxide(D2O). TSP (Trimethyl-silyl
propionic acid) was added which serves as both a chemical shift reference and
concentration standard for the proton NMR studies. Proton spectra were acquired
at a 700 MHz spectrometer. The spectral
regions at 0.5-10 ppm were segmented into bins with equal widths of 0.04 ppm. Statistical analysis was performed using SPSS (SPSS Inc., Chicago, IL, USA).
The t-test was used to analyze differences between groups. P values were
two-tailed and a value < 0.05 was considered significant. The data were normalized
and subjected to multivariate pattern recognition analysis using MetaboAnalyst
5.0 software. Metabolites were considered significant at VIP >1.0 for
further analysis of metabolomic data analysis.
Partial least square discriminant analysis (PLS-DA) and orthogonal
partial least square discriminant analysis (OPLS-DA) loading plots were carried
out for significant metabolite identification. Variable importance in
projection (VIP) scores in PLS-DAs of metabolic profiles in the tissue of
patients, VIP scores for some important metabolites with the highest contribution
to the separation of the studied groups are presented. The boxes on the right
refer to the relative concentrations of the appropriate metabolites in the
studied groups.
Results
Figure
1 Representative CPMG 1H NMR spectra of tissue spectra of aortic valve and
mitral valve. The tissue metabolomic profile of patients with aortic valves is
characterized by decreased levels of valine malonate, glycine, and myo-inositol
compared with mitral vales. The results obtained from PLS-DA and VIP score
plots of metabolites in tissue showed a separation between patients with aortic valves and mitral
valves shown in Figure.
Discussion
Significantly lower levels of valine malonate, glycine,
and myoinositol in aortic valve as compared to mitral valve disease tissue. NMR-based
metabolomics analysis enhanced the current understanding of the mechanisms
involved in human valves and
uncovered the therapeutic potential role of diseases. The disturbing metabolites
were proposed to be the potential biomarkers that may help to predict to
evaluate the efficacy of human valve diseases in the treatment. Myo-inositol is known to exert
anti-diabetic, anti-oxidative, and anti-inflammatory properties. The lower
level of Myo-inositol compromises the anti-inflammatory properties. In recent study, evidence has mounted in
favor of the anti-inflammatory, immunomodulatory, and cytoprotective effects of
the simplest amino acid L-glycine. The lower level of glycine compromises the anti-inflammatory
properties. Malonate associates oxidative stress and alteration ROS system.
Conclusion
The present study revealed discrimination
of metabolic profiling of tissue of aortic valve patients from mitral valve
replacement implying that 1H-NMR-based metabolomics may provide an
insight into understanding the potential metabolic alteration such as valine
malonate, glycine, and myo-inositol metabolism associated with inflammation, oxidative stress, and tissue degradation
of HVD.Acknowledgements
Thank for Department of NMR AIIMS New Delhi References
1. Fu B, Wang J, Wang L, Wang Q, Guo Z, Xu M,
Jiang N. Integrated proteomic and metabolomic profile analyses of cardiac
valves revealed molecular mechanisms and targets in calcific aortic valve
disease. Front Cardiovasc Med. 2022 Oct 13;9:944521.
2. Coffey
S, Roberts-Thomson R, Brown A, Carapetis J, Chen M, Enriquez-Sarano M, et al.
Global epidemiology of valvular heart disease. Nat Rev Cardiol. (2021)
18:853–64.
3. 2.
Yi B, Zeng W, Lv L, Hua P. Changing epidemiology of calcific aortic valve
disease: 30-year trends of incidence, prevalence, and deaths across 204
countries and territories. Aging (Albany NY). (2021) 13:12710–32.
4. Peltonen T, Ohukainen P, Ruskoaho H, Rysä J. Targeting vasoactive peptides for
managing calcific aortic valve disease. Ann Med. (2017) 49:63–74.
5.
Akahori H, Tsujino T, Masuyama T, Ishihara M. Mechanisms of aortic stenosis. J
Cardiol. (2018) 71:215–20.
6.